FIELD: medicinal chemistry.
SUBSTANCE: new compounds of formula (I), where the values of A, L, Y1, Y2, R1-R3, n1, n2, m1, m2 are defined in the claims, to a pharmaceutical composition containing such compounds, and to their use as inhibitors of menin-MLL protein-protein interactions.
EFFECT: useful in the treatment of diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
10 cl, 4 tbl, 198 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOUNDS | 2013 |
|
RU2654857C2 |
| PYRROLO-PYRROLE COMPOSITIONS AS ACTIVATORS OF PYRUVATE KINASE (PKR) | 2018 |
|
RU2736217C2 |
| PYRIDINES SUBSTITUTED WITH HETEROARYL AND APPLICATION METHODS | 2017 |
|
RU2756743C2 |
| PTERIDINES AS FGFR INHIBITORS | 2013 |
|
RU2702906C2 |
| DERIVATIVES OF 1,5- AND 1,7-NAPHTHYRIDINE USEFUL IN TREATMENT OF FGFR-MEDIATED DISEASES | 2012 |
|
RU2629194C2 |
| COMPOUNDS BASED ON PYRAZOLOPYRIDINONE | 2018 |
|
RU2806751C2 |
| COMPOUNDS BASED ON PYRAZOLOPYRIDINONE | 2018 |
|
RU2806625C2 |
| NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | 2018 |
|
RU2780577C2 |
| BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | 2004 |
|
RU2301802C2 |
| HETEROCYCLIC IMMUNOMODULATORS AS INHIBITOR OF IMMUNE RESPONSE CHECKPOINTS PDL1 | 2020 |
|
RU2824127C2 |
